

NOTICE

Notice is hereby given that the annual general meeting of shareholders (the **General Meeting**) of TME Pharma N.V. (the **Company**) is convened at 10.00 hours (CEST) on 15 June 2026 at Sheraton Amsterdam Airport Hotel & Conference Center, Schiphol Boulevard 101, 1118 BG Schiphol (adjacent to Schiphol Plaza via covered walkway adjacent to the arrivals hall and train station; on-site parking available). The language of the meeting shall be English.

You do not need to be present to cast your vote at the General Meeting on 15 June 2026. Instead, you can give your voting instructions by proxy. Further details on participation, voting or representation by proxy are given in the Attendance Notice for this General Meeting available on the Company's corporate website: <https://www.tmepharma.com> (the **Company's Website**).

Shareholders who decide not to attend the General Meeting on 15 June 2026 at Schiphol Airport, the Netherlands, and who wish to submit questions regarding items on the agenda of the General Meeting, may submit their questions by email to shareholders@tmepharma.com up to 17.00 hours (CEST) on 12 June 2026. The email submitting such question(s) must include name, surname, number of shares held by the shareholder on 18 May 2026 (the **Registration Date** as defined below) and the agenda item to which the question relates.

AGENDA

The General Meeting is convened to discuss and decide on the following:

Agenda

- 1. Opening**
- 2. Annual Accounts 2025**
 - a. Discussion of the annual report 2025 (discussion)
 - b. Decision not to distribute dividend (discussion)
 - c. Adoption of the annual accounts 2025 (voting)
 - d. Release from liability of the members of the board of directors (voting)
 - e. Release from liability of the members of the supervisory board (voting)
- 3. Appointment of Dr. Dirk Eulberg as member of the board of directors (voting)**
- 4. (Re-)appointment of members of the supervisory board**
 - a. Re-appointment of Dr. Maurizio PetitBon as member of the supervisory board (voting)
 - b. Re-appointment of Dr. Lee Schalop as member of the supervisory board (voting)
 - c. Appointment of Dr. Oscar Izeboud as new member of the supervisory board (voting)
- 5. Re-appointment of Baker Tilly (Netherlands) B.V. as statutory auditor for the financial year 2026 (voting)**



6. **Re-authorisation of the authorisation to the board of directors to acquire shares (voting)**
7. **Any other business**
8. **Close of meeting**

Berlin, Federal Republic of Germany, 21 May 2026

The board of directors

EXPLANATORY NOTES

Agenda item 2a — Discussion of the annual report 2025 (discussion)

The annual report 2025 is available through the Company's Website. This agenda item is a discussion item only.

Agenda item 2b — Decision not to distribute dividend (discussion)

In accordance with best practice provision 4.1.3 sub (iii) of the Dutch Corporate Governance Code, the Company's proposed (new) Reservation and Dividend Policy is placed on the agenda as a separate agenda item. In line with earlier years and the proposed (new) Reservation and Dividend Policy, the Company has not and will not declare any dividends for the financial year 2025. This agenda item is a discussion item only. Formal adoption of the Company's (new) Reservation and Dividend Policy is proposed under agenda item 7 below.

Agenda item 2c — Adoption of the annual accounts 2025 (voting)

The General Meeting is requested to vote on the adoption of the annual accounts of the Company for the financial year 2025.

Agenda item 2d — Release from liability of the members of the board of directors (voting)

The General Meeting is requested to vote to release all persons who were a member of the Company's board of directors during 2025 (or during a part of 2025) from liability for their management during 2025 insofar as such management is apparent from the financial statements or otherwise disclosed to the General Meeting prior to the adoption of the annual accounts. This release covers both Dr. Aram Mangasarian (sole member of the board of directors from 1 January 2025 until the close of the annual general meeting held on 25 June 2025) and Mr. Diede Mink van den Ouden (sole member of the board of directors from the close of that meeting until 31 December 2025).

Agenda item 2e — Release from liability of the members of the supervisory board (voting)

The General Meeting is requested to vote to release all persons who were a member of the Company's supervisory board in 2025 (or a part of 2025 only) from liability for their supervision on the management by the board of directors insofar as such supervision is apparent from the financial statements or otherwise disclosed to the General Meeting prior to the adoption of the annual accounts.

Agenda item 3 — Appointment of Dr. Dirk Eulberg as member of the board of directors (voting)

In order to expand the operational capacity of the board of directors and to support the continued execution of the Company's clinical development plan, the supervisory board has considered Dr. Dirk Eulberg for appointment as member of the board of directors. Pursuant to the articles of association of the Company, the supervisory board is making the binding nomination to appoint Dr. Dirk Eulberg as member of the board of directors.

Dr. Dirk Eulberg, 58 years old, is a German national. He has been involved with the Company and its predecessor NOXXON Pharma AG for over twenty-two years, most

recently as Senior VP Project Management and Preclinical Development between January 2023 and June 2025. Prior to that, he served as VP Project Management & Preclinical Development at NOXXON Pharma AG (2009–2022), VP Drug Discovery and Project Leader (2006–2009) and in earlier group-leader positions in biochemistry and automation (2000–2005). Since August 2025 he has provided drug development advisory services through his consultancy Eulberg Life Sciences Consulting. Dr. Eulberg holds a Ph.D. in Microbiology, Biochemistry and Molecular Biology from the University of Stuttgart and an MBA in Economics from the University of Potsdam. He combines more than twenty-five years of hands-on and strategic experience in pharmaceutical drug development from drug discovery up to clinical Phase 2.

The supervisory board considers Dr. Dirk Eulberg the right candidate to serve on the board of directors. During 2025, his involvement with the Company proved more extensive than originally anticipated — a reflection of the Company's increasing operational activity and the active progress of its clinical pipeline. His formal appointment as Chief Operating Officer is expected to be more cost-effective for the Company than continuing to engage him as an external consultant, and better reflects the scope and continuity of his contribution. While the appointment will give rise to additional remuneration costs relative to the earlier consultancy arrangement, the supervisory board notes that these costs are directly connected to the operational progress and deal-making activity that Dr. Eulberg has been instrumental in driving, and expects that they will, to a significant extent, be recoverable through the partnerships and transactions that the Company is actively pursuing. His engagement reinforces the operational and scientific leadership of the Company, preserves the deep institutional knowledge of NOX-A12 and the broader pipeline that he has accumulated over his career at NOXXON Pharma AG and TME Pharma N.V., and ensures continuity in the execution of the Company's clinical development plan.

Following the appointment, the board of directors will consist of two members: Mr. Diede Mink van den Ouden, the Company's Chief Executive Officer, with primary responsibility for finance, capital strategy and overall strategic direction, and Dr. Dirk Eulberg, who will assume the role of Chief Operating Officer with primary responsibility for the operational, scientific and IT activities of the Company. Both functions are complimentary to each other and the two directors will serve alongside each other on a collegial basis. Each managing director is/has been appointed as a managing director with full statutory responsibilities, and both directors report jointly to the supervisory board. The functional allocation of duties between the Chief Executive Officer and the Chief Operating Officer is intended to organise the day-to-day operations of the Company and does not derogate from the collective responsibility of the board of directors as a whole.

The job profiles of Dr. Dirk Eulberg and the CEO (Mr. Diede van den Ouden) and the proposed division of work between the managing directors are set out in **Annex 1** to these explanatory notes.

The term of office of Dr. Dirk Eulberg as member of the board of directors will be from the General Meeting up to and including the annual general meeting of shareholders to be held in 2028. Dr. Eulberg will be remunerated in accordance with the Company's remuneration policy; a description of the main terms of his appointment is attached to these explanatory notes as **Annex 2**.

Agenda item 4 — Re-appointment of members of the supervisory board

Mrs. Susan Coles has informed the supervisory board that she will voluntarily resign from her position as member of the supervisory board effective as per 30 June 2026. The

Company records its appreciation for Mrs. Coles' contribution to the supervisory board until now.

In accordance with the supervisory board rotation schedule (available on the Company's Website), the current term of office of Dr. Maurizio PetitBon and of Dr. Lee Schalop — both appointed on 27 June 2024 — will expire on the day of the General Meeting. Both have expressed their willingness to accept re-appointment into their respective offices. In furtherance of the profile and composition of the supervisory board (available on the Company's Website), the supervisory board has considered the contribution and performance of each of them and is of the view that they have demonstrated the desired commitment and respective expertise in their roles in the Company. The supervisory board has, pursuant to the articles of association of the Company, made the binding nominations set out under agenda items 4a and 4b.

Furthermore, in order to add specific M&A, business development and investment banking expertise to the supervisory board at this stage of the Company's development, the supervisory board has considered Mr. Oscar Izeboud for appointment as new member of the supervisory board (agenda item 4c).

Following these (re-)appointments, the supervisory board will consist of three members: Dr. Maurizio PetitBon, Dr. Lee Schalop and Dr. Oscar Izeboud. The Supervisory Directors will receive a remuneration in line with the Company's Remuneration Policy which can be found on the Company's website.

Following the General Meeting, the rotation schedule for the Supervisory Board Directors will be amended as per **Annex 3**.

Agenda item 4a — Re-appointment of Dr. Maurizio PetitBon as member of the supervisory board (voting)

Dr. Maurizio PetitBon, 78 years old, is an Italian national. His profession is healthcare and life-sciences investor and senior corporate advisor, and he currently holds no common or preference shares in the capital of the Company. Most recently, Dr. Maurizio PetitBon served as Senior Advisor to BlackRock following BlackRock's acquisition of Kreos Capital, where he was general partner and co-founder of one of Europe's leading private debt providers and headed the firm's healthcare investment activities. Before co-founding Kreos, he held senior consulting positions at PMA Europe (London and Milano) and at SRI International (Menlo Park, California, and London), advising U.S., European and Japanese technology companies and private equity funds on business development and M&A strategies. Earlier in his career, he held managerial positions at Emerson Electric, Digital Equipment and Xerox. Dr. Maurizio PetitBon holds a doctor's degree in mechanical engineering from the University of Rome. Outside the Company, he currently has no other supervisory or non-executive board positions.

Dr. Maurizio PetitBon has been a member of the supervisory board since 27 June 2024. The supervisory board considers his re-appointment desirable in light of his demonstrated commitment as a member of the supervisory board, his deep experience in healthcare financing and private debt and his familiarity with the Company's strategic and capital position. The General Meeting is requested to vote on his re-appointment for a further term of two years, from the General Meeting up to and including the annual general meeting of shareholders to be held in 2028.

Agenda item 4b — Re-appointment of Dr. Lee Schalop as member of the supervisory board (voting)

Dr. Lee Schalop, 62 years old, is a U.S. national based in New York. His profession is biotech entrepreneur and investor, and he holds no common or preference shares in the capital of the Company. Dr. Schalop is the founder of LSWorks LLC, a vehicle through which, since January 2011, he builds new companies in biotech, medical devices and life-sciences services together with scientific founders. He co-founded Oncoceutics, Inc., a clinical-stage drug discovery and development company with a novel brain-cancer drug, and served successively as its Chief Business Officer (2009–2016), Chief Operating Officer (2016–2020) and Chief Executive Officer until the sale of the company to Chimerix in January 2021. The drug that he developed at Oncoceutics, now called Modeyso (dordavirpone), was approved by the US FDA for treatment of adult and pediatric patients (1 year of age and older) with H3 K27M-mutant diffuse midline glioma (DMG) in August 2025. Before turning to biotech, Dr. Lee Schalop spent more than nineteen years in the financial industry — including as Managing Director at Banc of America Securities and in senior roles at JP Morgan, Credit Suisse and Morgan Stanley — first as an investment banker, where his fundraising activities included more than ten initial public offerings (the largest of which raised over USD 700 million), and then as a research analyst, where he authored more than 1,000 reports covering over fifty publicly traded companies. Dr. Lee Schalop holds an M.D. from the Albert Einstein College of Medicine (2008) and is a summa cum laude graduate of the University of Pennsylvania, where he earned dual degrees from the Wharton School and the College of Arts and Sciences. Outside the Company, he currently also serves on the Advisory Board of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania and on the Board of the City Parks Foundation in New York.

Dr. Lee Schalop has been a member of the supervisory board since 27 June 2024. The supervisory board considers his re-appointment desirable in light of his rare combination of medical and financial expertise, his entrepreneurial track record at the operational helm of a clinical-stage oncology company and his proven ability to support a small biotech through clinical development, financing and a strategic exit. The General Meeting is requested to vote on his re-appointment for a further term of two years, from the General Meeting up to and including the annual general meeting of shareholders to be held in 2028.

Agenda item 4c — Appointment of Dr. Oscar Izeboud as new member of the supervisory board (voting)

Dr. Oscar Izeboud (formal first names: Cornelius Alexander), 55 years old, is a Dutch national. His profession is chief executive officer and corporate-finance / life-sciences executive, and he currently holds no common or preference shares in the share capital of the Company. Dr. Izeboud previously served as a member of the supervisory board of the Company between July 2020 and the close of the annual general meeting held on 25 June 2025, when he stepped down to facilitate the reduction of the supervisory board to three members in line with the strategy of the Company at the time. In light of the Company's current strategic priorities — in particular the evaluation of partnership, licensing and exit alternatives in support of the Company's capital strategy — the supervisory board considers it desirable to re-engage his expertise.

Since July 2020, Dr. Oscar Izeboud has served as Chief Executive Officer and executive member of the board of directors of Scenic Biotech B.V. (Amsterdam), where he led R&D collaborations with Genentech (2020), Bristol Myers Squibb (2023), Alnylam (2025) and Ono Pharmaceutical (2026), the company's Series A financing in 2022 and a CRADA with the U.S. National Institutes of Health. Prior to Scenic Biotech, he was Managing Director

Corporate Finance — Capital Markets and Head of Life Sciences and Healthcare at NIBC Bank (2017–2020) and held the same position at Kempen & Co for more than eleven years (2006–2017), where he led numerous biotech IPOs — including Galapagos, Ablynx, Argen-X (Brussels and Nasdaq), Biocartis, Kiadis and Probiodrug — and cross-border M&A transactions in the life-sciences sector. He started his career at TNO (1996–2004) and Crucell (2004–2006, now part of Johnson & Johnson). Dr. Izeboud holds a Ph.D. in Pharmacology from Utrecht University and an M.Sc. in Biopharmaceutical Sciences / Chemistry from Universiteit Leiden. Outside his executive role at Scenic Biotech, he is a co-owner of Kaapse Brouwers (Rotterdam, since 2019); his most recent independent board roles at Nomad Bioscience GmbH (Halle, Germany — until November 2025) and LoopLab Bio (Vienna, Austria — until February 2026) have come to an end.

The supervisory board considers his re-appointment desirable because his combined experience as a life-sciences chief executive officer and as a corporate-finance and capital-markets professional in the European biotech sector complements — without overlapping — the existing competencies of Dr. Maurizio PetitBon and Dr. Lee Schalop. Within the supervisory board, his focus will be on supporting the board of directors in (i) identifying and structuring strategic transactions, including partnership and licensing arrangements with pharmaceutical and biotechnology companies, (ii) evaluating financing alternatives and capital-markets transactions and (iii) developing and assessing potential exit scenarios for the benefit of the Company and its shareholders.

The term of office of Dr. Oscar Izeboud as member of the supervisory board will be two years, from the General Meeting up to and including the annual general meeting of shareholders to be held in 2028.

Agenda item 5 — Re-appointment of Baker Tilly (Netherlands) B.V. as statutory auditor for the financial year 2026 (voting)

Based on the Audit Committee's assessment of the functioning of Baker Tilly (Netherlands) B.V. as external auditor in respect of the audit of the annual accounts for the financial year 2025 and its recommendation to the supervisory board, the board of directors and the supervisory board propose to re-appoint Baker Tilly (Netherlands) B.V. as statutory auditor. This agenda item proposes to appoint Baker Tilly (Netherlands) B.V. as statutory auditor for the financial year 2026.

Agenda item 6 — Re-authorisation of the authorisation to the board of directors to acquire shares (voting)

The existing authorisation of the board of directors as the corporate body competent to repurchase ordinary shares in the Company's own share capital, granted by the General Meeting held on 25 June 2025 for a period of eighteen months, will expire on 24 December 2026. As that date falls before the next annual general meeting of shareholders (expected to be held in 2027), and to preserve the Company's ability to continue supporting the liquidity of its shares through a liquidity agreement with an authorised investment services provider (in compliance with the charters of ethics approved by the French Autorité des Marchés Financiers (AMF) and the French Association of the Financial Markets (AMAFI)), it is proposed to renew the authorisation already at the 2026 General Meeting.

It is therefore proposed to designate the board of directors to repurchase ordinary shares in the Company's own share capital for the same purpose, through stock exchange trading or otherwise, up to 10% of the issued and outstanding ordinary share capital, at any time during a period of eighteen months as of the day of the General Meeting (i.e. up to and including 14



December 2027) against a repurchase price between EUR 0.01 and EUR 50.00, with the prior approval of the supervisory board.

ANNEX 1 — JOB PROFILES OF THE MEMBERS OF THE BOARD OF DIRECTORS

The following job profiles describe the proposed division of work between the two members of the board of directors of TME Pharma N.V. as from the close of the General Meeting on 15 June 2026, subject to the approval of agenda item 3.

Job profile — Mr. Diede Mink van den Ouden, Chief Executive Officer

Position: Chief Executive Officer (member of the board of directors)

Reports to: Supervisory board

Location: Berlin, Germany / Switzerland (combination of on-site and remote)

Job description

The Chief Executive Officer is responsible for the overall management and strategic direction of TME Pharma N.V. and chairs the two-member board of directors. The Chief Executive Officer leads the Company's interaction with capital markets, lenders and investors, develops and executes the financing and reorganisation strategy required to support the Company's clinical development plan, and manages the relationship with the supervisory board.

Field of expertise

- Capital markets, equity issuance and debt restructuring of listed companies.
- Corporate strategy and turnaround management of Euronext-listed companies.
- Investor relations, shareholder communication and transparent reporting.
- Financial planning, treasury and risk management.
- Listed-company governance under the Dutch Corporate Governance Code, the AMF/AMAFI framework and Euronext Growth Paris rules.

Professional and educational background

- More than twenty years of hands-on experience as a professional investor in, and chief executive of, listed companies.
- Chief Executive Officer of TME Pharma N.V. since June 2025.
- Chief Executive Officer and President of Tonner Drones SA (listed on Euronext Growth Paris) since September 2024, after leading a debt restructuring and a EUR 5 million capital increase that grew its market capitalisation from EUR 2 million to approximately EUR 20 million.
- President of the Board of Directors of MHM Corporate SA (listed on Euronext Paris) since December 2025; also served as Chief Executive Officer from December 2025 until February 2026.
- Chief Executive Officer of Lavide Holding NV from December 2022 until November 2024, where he led a full reorganisation that culminated in a strategic partnership with Haerlem Capital.
- Founder and Chief Executive Officer of Kennie Capital BV (family office) from 2017 until 2024.
- Studied Human Movement Science at the Vrije Universiteit Amsterdam.



Duties and responsibilities

- Day-to-day management and governance: chairs the two-member board of directors and is responsible for the overall day-to-day policies, strategy and external representation of TME Pharma.
- Finance and capital strategy: develops and executes the Company's financing strategy, including equity raises, debt extensions, refinancing transactions and warrant programmes, and manages the relationship with lenders, banks and capital-markets advisers.
- Investor relations: leads communication with shareholders, lenders and the broader market, including press releases, AGM preparation and investor meetings.
- Strategic transactions: in close coordination with the supervisory board, evaluates and structures partnership opportunities, licensing arrangements and exit alternatives.
- Coordination: works alongside the Chief Operating Officer to ensure that operational, scientific and financial activities are aligned with the Company's strategy.
- IT and infrastructure: supports vendor management and ensures the security and continuity of the Company's IT infrastructure in coordination with the Chief Operating Officer.



Job profile — Dr. Dirk Eulberg, Chief Operating Officer

Position: Chief Operating Officer (member of the board of directors)

Reports to: Supervisory board

Location: Berlin, Germany

Job description

The Chief Operating Officer is responsible for the operational, scientific and IT activities of TME Pharma N.V. and serves alongside the Chief Executive Officer on the two-member board of directors. The Chief Operating Officer ensures the continued execution of the Company's clinical development plan for NOX-A12 and the broader pipeline, manages the network of contract research organisations (CROs), academic partners and external consultants, and oversees the IT infrastructure and information security of the Company.

Field of expertise

- Pharmaceutical drug development from drug discovery up to clinical Phase 2 studies in patients.
- Non-clinical (GLP-compliant) safety, DMPK and pharmacology studies and the necessary analytical support.
- CTA/IND applications, Scientific Advice procedures, Orphan Drug Designation and Fast Track Designation requests.
- Project management, CRO management, prioritisation of project portfolios and due diligence of in-licensing or investment opportunities.
- IT systems and infrastructure for biotech operations, including data security and vendor management.

Professional and educational background

- Doctor of Philosophy (Ph.D.) in Microbiology, Biochemistry and Molecular Biology, University of Stuttgart.
- MBA in Economics, University of Potsdam.
- More than 25 years of hands-on and strategic experience in pharmaceutical drug development.
- Senior VP Project Management and Preclinical Development at TME Pharma N.V. from January 2023 until June 2025.
- VP Project Management & Preclinical Development at NOXXON Pharma AG from October 2009 until December 2022, and previously VP Drug Discovery and Project Leader (2006–2009) and Group Leader Biochemistry / Group Leader Automation (2000–2005) at the same company.
- Founder of Eulberg Life Sciences Consulting (since August 2025), through which he has provided drug development advisory services to pharmaceutical and biotechnology companies.

Duties and responsibilities

- Operations: day-to-day operational management of TME Pharma's pipeline activities, including planning, monitoring and reporting of clinical and preclinical milestones for NOX-A12 and E36.
- Scientific and project management: leadership of the project teams responsible for NOX-A12, E36 and any further pipeline assets, including management of the network



of CROs, academic partners and external consultants. Manages and protects the Company's patent portfolio.

- Governance: prepares board and supervisory board presentations, coordinates board meetings and manages the related logistics, and maintains corporate records including minutes.
- Regulatory: preparation and management of CTA/IND filings, Scientific Advice procedures and Orphan Drug / Fast Track requests.
- IT and infrastructure: development, maintenance and security of the Company's IT infrastructure, vendor management and continued protection of clinical and scientific data in coordination with the CEO.
- Quality and compliance: implementation and monitoring of operational quality standards, including GLP/GCP-compliant studies.

ANNEX 2 – MAIN TERMS OF APPOINTMENT FOR DR. DIRK EULBERG

Employing entity	TME Pharma N.V.
Function Title	Chief Operating Officer (COO)
Board member position	Board of Directors
Annual base salary	€ 7,200 gross (excluding mandatory employer's contribution to social security, if any) per month based on a part- time basis.
Initial equity	<p>Initial grant of stock options of up to 0.2% of the issued share capital of TME Pharma N.V. outstanding at the time of the Euronext Growth Paris stock exchange market's closing on the day the stock option agreement is fully executed (the "Grant Date").</p> <p>25% of these stock options will vest on the Grant Date, and the remainder will vest at the rate of 25% on each of 1st, 2nd and 3rd anniversary of the Grant Date should he continue to be employed by the Company.</p> <p>As of the date of this publication such initial grant would amount to 188,377 options.</p>
Fringe benefits	Additional fringe benefits.

ANNEX 3 – ROTATION SCHEDULE FOR THE SUPERVISORY BOARD DIRECTORS

1. BACKGROUND

1.1. This rotation schedule for the supervisory board directors has been established by the supervisory board (the **Supervisory Board**) of TME Pharma N.V. (the **Company**) pursuant to article 2 paragraph 9 of the supervisory board rules of the Company (the **Supervisory Board Rules**) and amended on 15 June 2026.

1.2 Under the articles of association of the Company and the Supervisory Board Rules, supervisory board directors are appointed for a two-year term. A supervisory board director may be re-appointed. The supervisory board directors shall retire periodically in accordance with this rotation schedule. A supervisory board director shall retire early in the event of inadequate performance, structural incompatibility of interests, and in other instances in which this is deemed necessary by the Board of the Company.

Name	Date of (Re-)Appointment	Term expiration & expected retirement if different from expiration
Dr. C. A. Izeboud	15 June 2028	The annual general meeting of shareholders in 2028
Dr. Maurizio PetitBon	15 June 2028	The annual general meeting of shareholders in 2028
Dr. Lee Schalop	15 June 2028	The annual general meeting of shareholders in 2028

1.3. The Board will review and where appropriate amend the rotation schedule to avoid as much as possible the situation that all supervisory board directors retire at the same time.

ATTENDANCE INFORMATION

General Meeting documentation

The General Meeting documentation:

- annual accounts and report of the board of directors for 2025;
- agenda and the explanatory notes to the agenda;
- job profiles for the members of the Board of Directors;
- description of the main terms of Dr. Dirk Eulberg's appointment;
- rotation schedule for the Supervisory Board Directors; and
- instructions and documents for participation and voting at the General Meeting

are available on the Company's Website. These documents are also available at the Company's offices at Max-Dohrn-Strasse 8-10, 10589 Berlin, Federal Republic of Germany, for shareholders and persons entitled to attend the meeting who, upon request, will receive a copy free of charge.

Participation and voting

Under Dutch law and the Company's articles of association, persons entitled to attend and to vote at the General Meeting are shareholders of the Company (which for the purposes of this notice includes holders of a Dutch law right of usufruct and/or a right of pledge (if applicable and if such right includes meeting rights)) who (i) were registered as shareholder in one of administration records of the intermediaries that are (indirectly) participants in Euroclear France on 18 May 2026 (the **Registration Date**) after all debit and credit entries have been handled as per the Registration Date and (ii) have notified the Company by 17.00 hours (CEST) on 8 June 2026 of their attendance in writing or electronically (contact details at the end of this announcement) and (iii) have presented the Company with a broker statement evidencing that they were a shareholder of the Company on the Registration Date and stating the number of shares in the capital of the Company held. You do not need to be present to cast your vote at the General Meeting on 15 June 2026. Instead, you can give your voting instructions by proxy.

Representation by proxy

Subject to compliance with the provisions above, shareholders who cannot attend and vote at the General Meeting in person, may also be represented at the General Meeting by proxy. In order to be eligible to give proxy and voting instructions, the relevant shareholder must ensure that (i) he or she is registered as a shareholder in the manner as described above and (ii) the duly completed and signed proxy including, as appropriate, voting instructions, are received by the Company by 17.00 hours (CEST) on 8 June 2026 in writing or electronically (contact details at the end of this announcement). Shareholders who cannot attend and vote in person, are urged to give proxy and voting instructions to Mr. Arie van den Bergen, attorney at law (*advocaat*) with Finnicks Legal B.V., by completing the power of attorney form available on the Company's Website under "Attendance notice and PoA".



Attendance card

Shareholders who have notified the Company of their attendance (either in person or by proxy), will receive an attendance card issued in their name. This will serve as admission certificate and prior to the start of the General Meeting, the shareholder (or his or her proxy) will need to hand over the attendance card, and as applicable the written power of attorney, at the registration desk before being allowed to enter the General Meeting.

Identification

Persons entitled to attend the General Meeting may be requested to identify themselves at the registration desk prior to admission to the General Meeting and are therefore requested to bring a valid identity document.

Address details of the Company:

TME Pharma N.V.
Attn: Diede van den Ouden
Max-Dohrn-Strasse 8-10
10589 Berlin
Federal Republic of Germany
e-mail: shareholders@tmepharma.com